NEW YORK (Reuters Health) – For locally advanced and metastatic prostate cancer, the best timing and duration of androgen-deprivation therapy (ADT) is unclear. Now, a systematic review suggests immediate and sustained treatment leads to best results, especially when combined with local treatment.

“Irradiation or surgical removal of the primary tumor appears to be a necessary condition to fully benefit from prolonged (i.e., >6 mo) ADT,” lead author Dr. Paul C.M.S. Verhagen, of Erasmus MC in Rotterdam, Holland, and colleagues report online May 27th in European Urology.

They add that not all patients with T3 and/or node-positive disease will need combined treatment, and that those expected to die within three to five years are most likely to benefit.

“Whether the survival advantage of combined treatment is large enough to counterbalance the side-effects of prolonged ADT and local treatment is an issue that has to be settled in discussion with an informed patient,” they say.

Dr. Verhagen and colleagues analyzed 17 reports of 14 randomized studies of prostate cancer treatment published since 1970. They included those that reported cancer-specific and overall survival for immediate vs. deferred ADT (orchiectomy or luteinizing hormone-releasing hormone) or adjuvant ADT.

For immediate vs. deferred ADT, meta-analysis of data from five studies showed significant improvements in overall (hazard ratio, 0.90) and cancer-specific survival (HR, 0.79). However, the researchers note that treatment lasted substantially longer in the immediate ADT group.

“With the well-documented side-effects of prolonged exposure to ADT” — including erectile dysfunction, fatigue and depression — “many clinicians argue that in this setting, the modest benefit does not outweigh the disadvantages for most patients,” Dr. Verhagen and colleagues say.

The 5 trials of adjuvant ADT showed a greater effect on survival, but also more heterogeneity; the duration of ADT varied from six months to life-long. Meta-analysis, which showed that adjuvant ADT significantly reduced overall mortality (HR, 0.69) and prostate cancer deaths (HR, 0.51).

The researchers argue that results cannot be explained by the radiosensitizing effects of ADT alone, but must involve systemic effects.

“Among other important points, the authors highlight the body of evidence that ADT alone is not optimal treatment for localized prostate cancer,” Dr. Philip J. Saylor of Massachusetts General Hospital in Boston, who was not involved in the study, told Reuters Health by e-mail.

“The available literature clearly supports the use of neoadjuvant/concomitant/adjuvant ADT in men receiving primary radiation therapy for prostate tumors that are at intermediate to high risk for later relapse,” he added. “In patients with high risk/locally advanced disease, results of the EORTC trial published by Bolla et al in 2009 are particularly important as they clearly demonstrate a survival advantage for long term (3 years) ADT when compared with short term (6 months) ADT.” (See Reuters Health story of Jun 10, 2009.)

Reference:

http://www.europeanurology.com/article/S0302-2838%2810%2900464-1/fulltext

Eur Urol 2010.